Previous Close | 0.2000 |
Open | 0.2000 |
Bid | 0.0500 |
Ask | 0.3000 |
Strike | 15.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.2000 - 0.2000 |
Contract Range | N/A |
Volume | |
Open Interest | 12 |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results
IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki